Citryll

About:

Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.

Top Investors: BrightGene, Seventure Partners, BOM, BioGeneration Ventures, BOM Brabant Ventures

Description:

Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll was established in 2015 and is headquartered in Oss, The Netherlands.

Total Funding Amount:

18.5M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oss, Noord-Brabant, The Netherlands

Founded Date:

2015-01-01

Contact Email:

info(AT)citryll.com

Founders:

Helmuth van Es, Renato Chirivi

Number of Employees:

11-50

Last Funding Date:

2020-07-02

IPO Status:

Private

Industries: